Company intelligence / Profile preview
MoonLake Immunotherapeutics
- Ownership
- Public · MLTX
- Development stage
- Other
Overview
MoonLake Immunotherapeutics has advanced its lead asset, sonelokimab—a novel investigational Nanobody® targeting all relevant IL‑17 dimers—into multiple late-stage clinical trials. The company’s VELA Phase III program in hidradenitis suppurativa has completed patient recruitment with a primary endpoint readout expected soon. Interim results from the LEDA Phase II study in palmoplantar pustulosis have been reported earlier than anticipated, further de-risking development. Across eight active clinical trials, sonelokimab continues to show promise for inflammatory diseases with high unmet need.
- Therapeutic areas
- DermatologyRheumatology
- Modalities
- Nanobodies® (single-domain antibodies)Antibodies (specifically, humanized nanobodies)
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Financials
- Market cap
- $919.2M
- Total revenue
- $0
- Enterprise value
- $522.3M
Beyond the preview
Go deeper on MoonLake Immunotherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MoonLake Immunotherapeutics.